Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atorvastatin + methylprednisolone
- Development stage
- Preclinical
- Lead developer
- Pfizer
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous, Intramuscular
01
Overview
Atorvastatin + methylprednisolone is a combination of two small molecule drugs used together for their complementary therapeutic effects. Atorvastatin is an HMG-CoA reductase inhibitor (statin) that lowers cholesterol levels and exerts anti-inflammatory and vasculoprotective effects. Methylprednisolone is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties. This combination has been studied in conditions such as multiple sclerosis relapse, where it demonstrated improved outcomes compared to glucocorticosteroid monotherapy, including reduced disability progression, fewer brain lesions, extended time to relapse, and modulation of inflammatory cytokines[2]. Preclinical studies also suggest benefit in inflammatory diseases like rheumatoid arthritis when both agents are combined[4].
- Other names
- atorvastatin and methylprednisoloneatorvastatin calcium + methylprednisolone
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on atorvastatin + methylprednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atorvastatin + methylprednisolone.